RU2015115137A - PEPTIDES OBTAINED FROM p16INK4a FOR PREVENTION AND TREATMENT OF HPV-ASSOCIATED TUMORS AND OTHER TUMORS EXPRESSING p16INK4a - Google Patents

PEPTIDES OBTAINED FROM p16INK4a FOR PREVENTION AND TREATMENT OF HPV-ASSOCIATED TUMORS AND OTHER TUMORS EXPRESSING p16INK4a Download PDF

Info

Publication number
RU2015115137A
RU2015115137A RU2015115137A RU2015115137A RU2015115137A RU 2015115137 A RU2015115137 A RU 2015115137A RU 2015115137 A RU2015115137 A RU 2015115137A RU 2015115137 A RU2015115137 A RU 2015115137A RU 2015115137 A RU2015115137 A RU 2015115137A
Authority
RU
Russia
Prior art keywords
tumor
vector
fragment
virus
nucleic acid
Prior art date
Application number
RU2015115137A
Other languages
Russian (ru)
Other versions
RU2626542C2 (en
Inventor
Маттиас КЛООР
Мириам РОЙШЕНБАХ
КНЕБЕЛЬ-ДЁБЕРИЦ Магнус ФОН
Original Assignee
Рупрехт-Карлс-Университэт Гейдельберг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рупрехт-Карлс-Университэт Гейдельберг filed Critical Рупрехт-Карлс-Университэт Гейдельберг
Publication of RU2015115137A publication Critical patent/RU2015115137A/en
Application granted granted Critical
Publication of RU2626542C2 publication Critical patent/RU2626542C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/001149—Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464448—Regulators of development
    • A61K39/464449—Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (26)

1. Фрагмент ингибитора циклин-зависимой киназы pl6INK4a, способный индуцировать иммунный ответ против pl6INK4a и состоящий из1. A fragment of an inhibitor of cyclin-dependent kinase pl6 INK4a , capable of inducing an immune response against pl6 INK4a and consisting of (a) любой из следующих аминокислотных последовательностей:(a) any of the following amino acid sequences: (a1) MEPAAGSSMEPSADWLATAAARGRV(a 1 ) MEPAAGSSMEPSADWLATAAARGRV (a2) TAAARGRVEEVRALLEAGALPNAPNSY(a 2 ) TAAARGRVEEVRALLEAGALPNAPNSY (a3) LPNAPNSYGRRPIQVMMMGSARVAELL;(a 3 ) LPNAPNSYGRRPIQVMMMMGSARVAELL; (a4) VMMMGSARVAELLLLHGAEPNCADPATLTR;(a 4 ) VMMMGSARVAELLLLHGAEPNCADPATLTR; (a5) ADPATLTRPVHDAAREGFLDTLVVLHRAGARL;(a 5 ) ADPATLTRPVHDAAREGFLDTLVVLHRAGARL; (a6) HRAGARLDVRDAWGRLPVDLAEELGHRDVAR;(a 6 ) HRAGARLDVRDAWGRLPVDLAEELGHRDVAR; (a7) GHRDVARYLRAAAGGTRGSNHARIDAAEGPSDIPD;(a 7 ) GHRDVARYLRAAAGGTRGSNHARIDAAEGPSDIPD; (b) функционального эквивалента фрагмента (a), который все еще способен индуцировать иммунный ответ против pl6INKa; или(b) the functional equivalent of fragment (a), which is still capable of inducing an immune response against pl6 INKa ; or (c) комбинации фрагментов (a) и/или (b).(c) a combination of fragments (a) and / or (b). 2. Последовательность нуклеиновой кислоты, кодирующая фрагмент по п. 1 или вектор, содержащий указанную последовательность нуклеиновой кислоты.2. A nucleic acid sequence encoding a fragment according to claim 1 or a vector containing the specified nucleic acid sequence. 3. Вектор по п. 2, отличающийся тем, что указанный вектор представляет собой плазмиду или вирусный вектор.3. The vector according to claim 2, characterized in that said vector is a plasmid or viral vector. 4. Вирусный вектор по п. 3, отличающийся тем, что указанный вирусный вектор представляет собой поксвирус, аденовирус, ретровирус, вирус герпеса, вектор на основе альфа-вируса или аденоассоциированный вирус (AAV).4. The viral vector according to claim 3, characterized in that said viral vector is poxvirus, adenovirus, retrovirus, herpes virus, alpha virus-based vector or adeno-associated virus (AAV). 5. Поксвирус по п. 4, отличающийся тем, что указанный поксвирус представляет собой вирус коровьей оспы, NYVAG, avipox вирус, вирус оспы канареек, ALVAC, ALVAC (2), вирус куриной оспы или TROVAC.5. Poxvirus according to claim 4, characterized in that said poxvirus is vaccinia virus, NYVAG, avipox virus, canary pox virus, ALVAC, ALVAC (2), chicken pox virus or TROVAC. 6. Фармацевтическая композиция, содержащая фрагмент по п. 1, нуклеиновую кислоту по п. 2 или вектор по любому из пп. 2-5.6. A pharmaceutical composition comprising a fragment according to claim 1, a nucleic acid according to claim 2, or a vector according to any one of claims. 2-5. 7. Применение фрагмента по п. 1, нуклеиновой кислоты по п. 2 или вектора по любому из пп. 2-5 для получения вакцины для профилактики и лечения pl6INK4a - экспрессирующей пренеоплазии, неоплазии или опухоли.7. The use of the fragment according to claim 1, the nucleic acid according to claim 2, or the vector according to any one of claims. 2-5 to obtain a vaccine for the prevention and treatment of pl6 INK4a - expressing preneoplasia, neoplasia or tumor. 8. Фрагмент по п. 1, нуклеиновая кислота по п. 2 или вектор по любому из пп. 2-5 для применения в способе профилактики или лечения pl6INK4a - экспрессирующей пренеоплазии, неоплазии или опухоли.8. The fragment according to claim 1, the nucleic acid according to claim 2, or the vector according to any one of claims. 2-5 for use in a method for the prevention or treatment of pl6 INK4a - expressing preneoplasia, neoplasia or tumor. 9. Применение по п. 7 или 8, отличающееся тем, что указанная pl6 - экспрессирующая опухоль является запущенной карциномой.9. The use according to claim 7 or 8, characterized in that said pl6-expressing tumor is a neglected carcinoma. 10. Применение по п. 7 или 8, отличающееся тем, что указанная опухоль представляет собой запущенную саркому.10. The use according to claim 7 or 8, characterized in that said tumor is a neglected sarcoma. 11. Применение по п. 7 или 8, отличающееся тем, что указанная опухоль представляет собой аногенитальную опухоль или опухоль головы и шеи.11. The use according to claim 7 or 8, characterized in that said tumor is an anogenital tumor or a tumor of the head and neck. 12. Применение по п. 7 или 8, отличающееся тем, что указанная опухоль представляет собой опухоль желудочно-кишечного или гепатопанкреатобилиарного тракта; опухоль кожи или опухоль дыхательных путей.12. The use according to claim 7 or 8, characterized in that said tumor is a tumor of the gastrointestinal or hepatopancreatobiliary tract; swelling of the skin or swelling of the airways. 13. Применение по п. 7 или 8, отличающееся тем, что указанная опухоль представляет собой опухоль почек и мочевыводящеих путей, молочной железы, яичников, эндометрия или простаты.13. The use according to claim 7 or 8, characterized in that said tumor is a tumor of the kidneys and urinary tract, breast, ovaries, endometrium or prostate. 14. Применение по п. 7 или 8, отличающееся тем, что указанная опухоль представляет собой опухоль нервной системы, включая опухоль мозга.14. The use according to claim 7 or 8, characterized in that said tumor is a tumor of the nervous system, including a brain tumor. 15. Применение по п. 7 или 8, отличающееся тем, что указанная опухоль представляет собой опухоль, индуцированную ВПЧ.15. The use of claim 7 or 8, wherein said tumor is an HPV-induced tumor. 16. Применение по п. 11, отличающееся тем, что указанная аногенитальная карцинома представляет собой цервикальную карциному.16. The use according to claim 11, characterized in that said anogenital carcinoma is a cervical carcinoma.
RU2015115137A 2012-12-13 2012-12-13 PEPTIDES OBTAINED FROM p16INK4a FOR PREVENTION AND TREATMENT OF HPV-ASSOCIATED TUMOURS AND OTHER TUMOURS EXPRESSING p16INK4a RU2626542C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/005155 WO2014090266A1 (en) 2012-12-13 2012-12-13 P16ink4a derived peptides for prophylaxis and therapy of hpv-associated tumors and other p16 expressing tumors

Publications (2)

Publication Number Publication Date
RU2015115137A true RU2015115137A (en) 2017-01-18
RU2626542C2 RU2626542C2 (en) 2017-07-28

Family

ID=47552937

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015115137A RU2626542C2 (en) 2012-12-13 2012-12-13 PEPTIDES OBTAINED FROM p16INK4a FOR PREVENTION AND TREATMENT OF HPV-ASSOCIATED TUMOURS AND OTHER TUMOURS EXPRESSING p16INK4a

Country Status (5)

Country Link
KR (1) KR101665410B1 (en)
CN (1) CN104837497B (en)
BR (1) BR112015013863A2 (en)
RU (1) RU2626542C2 (en)
WO (1) WO2014090266A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016026919A1 (en) * 2014-08-20 2016-02-25 Ruprecht-Karls-Universität Heidelberg Vaccines and manufacturing methods for treatment and prevention of disease
CN106046156A (en) * 2016-06-02 2016-10-26 吉林大学 Preparation and application of cancer-related gene CDKN2A epitope polypeptide monoclonal antibody
CN108558996A (en) * 2018-01-11 2018-09-21 广州江元医疗科技有限公司 A kind of monoclonal antibody combined with p16 protein-specifics and its application in kit
CN114163512A (en) * 2021-03-24 2022-03-11 深圳市新靶向生物科技有限公司 Antigenic peptide combination related to liver cancer driver gene mutation and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2573105B1 (en) * 2011-09-21 2015-10-28 Ruprecht-Karls-Universität Heidelberg p16INK4a derived peptides for prophylaxis and therapy of HPV-associated tumors and other p16INK4a expressing tumors

Also Published As

Publication number Publication date
KR101665410B1 (en) 2016-10-12
WO2014090266A1 (en) 2014-06-19
CN104837497B (en) 2018-06-29
CN104837497A (en) 2015-08-12
KR20150084059A (en) 2015-07-21
RU2626542C2 (en) 2017-07-28
BR112015013863A2 (en) 2017-07-11

Similar Documents

Publication Publication Date Title
RU2015115137A (en) PEPTIDES OBTAINED FROM p16INK4a FOR PREVENTION AND TREATMENT OF HPV-ASSOCIATED TUMORS AND OTHER TUMORS EXPRESSING p16INK4a
ES2848064T3 (en) Therapeutic immunity-enhancing vaccine for HPV and related diseases
US8420389B2 (en) Nipah virus vaccines
JP2014207903A5 (en)
EP3045181B1 (en) A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV)
AU2007241405A1 (en) HPV-18-based papillomavirus vaccine
MX2019001769A (en) T cell receptors and immune therapy using the same.
JP2012509678A5 (en)
JP2009534332A (en) Papillomavirus vaccine
JP2016074727A5 (en)
RU2015115785A (en) SIT-SPECIFIC PEPTIDES WITH A DISPLACED READING FRAME (PRS) FOR THE PREVENTION AND TREATMENT OF CANCER
US20140120133A1 (en) Vaccine Against African Horse Sickness Virus
AU2018287159A1 (en) Personalized vaccine
Bissa et al. A prime/boost strategy using DNA/fowlpox recombinants expressing the genetically attenuated E6 protein as a putative vaccine against HPV-16-associated cancers
ES2558729T3 (en) Biomarker for patient selection and related procedures
DK2572725T3 (en) MSI-specific frameshift peptides (FSP) for the prevention and treatment of cancer
RU2017125494A (en) Recombinant Swine Pox Virus (SWINEPOX) and Vaccines
Radaelli et al. A prime/boost strategy by DNA/fowlpox recombinants expressing a mutant E7 protein for the immunotherapy of HPV-associated cancers
CA2909225C (en) Mutant vaccinia virus strains, uses thereof and method of producing the same
JP2010523138A5 (en)
DK2573105T3 (en) p16INK4a-derived peptides for the prevention and therapy of HPV-associated tumors and other tumors expressing p16INK4a
AU2014218358B2 (en) Vaccine against african horse sickness virus
JP2014118361A5 (en)
Schnierle et al. Recombinant poxvirus vaccines in biomedical research
RU2019107582A (en) VIRAL VACCINES